VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...

Verve Therapeutics (NASDAQ:VERV) stock gains as the company wins the FDA fast track designation for VERVE-102, a cholesterol ...

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

Verve Therapeutics has won U.S. Food and Drug Administration fast-track designation for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis.

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...

BOSTON - The U.S. Food and Drug Administration (FDA) has awarded Fast Track designation to Verve Therapeutics’ (NASDAQ:VERV) VERVE-102, a gene-editing treatment aimed at patients with ...

Verve Therapeutics has won U.S. Food and Drug Administration fast-track designation for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis. Verve on Friday said the ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate. Arcturus on Thursday said the designation ...

The Emirates Drug Establishment (EDE) has approved new indications for Guselkumab, making the UAE the second country globally to authorise the treatment for Crohn’s disease. Guselkumab is set to ...